130A
Veritas In Silico Inc.
Ｖｅｒｉｔａｓ Ｉｎ Ｓｉｌｉｃｏ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Dec 2023
360,356
Dec 2024
194,643
Dec 2025
91,140
Operating profit(thousand JPY)
Dec 2023
37,623
Dec 2024
-212,851
Dec 2025
-396,748
Operating profit margin(%)
Dec 2023
10.44
Dec 2024
-109.35
Dec 2025
-435.32
Profit before tax(thousand JPY)
Dec 2023
35,898
Dec 2024
-233,562
Dec 2025
-421,946
Profit(thousand JPY)
Dec 2023
33,048
Dec 2024
-236,442
Dec 2025
-425,671
Total assets(thousand JPY)
Dec 2023
1,655,531
Dec 2024
2,248,958
Dec 2025
1,884,912
Cash and cash equivalents(thousand JPY)
Dec 2023
1,549,111
Dec 2024
173,358
Dec 2025
325,213
Cash flows from operating activities(thousand JPY)
Dec 2023
68,710
Dec 2024
-217,944
Dec 2025
-299,265
Cash flows from investing activities(thousand JPY)
Dec 2023
-2,031
Dec 2024
-2,005,988
Dec 2025
451,119
Cash flows from financing activities(thousand JPY)
Dec 2023
-2,000
Dec 2024
848,179
Dec 2025
-
Return on equity(%)
Dec 2023
2.1
Dec 2024
-
Dec 2025
-
Equity ratio(%)
Dec 2023
95.2
Dec 2024
98.2
Dec 2025
94.6
Earnings per share(JPY per share)
Dec 2023
6.01
Dec 2024
-37.11
Dec 2025
-65.62
Net assets per share(JPY per share)
Dec 2023
286.41
Dec 2024
340.61
Dec 2025
274.99
Dividend per share(-)
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.